During Wednesday’s Current trade, Shares of Computer Sciences Corporation (NYSE:CSC), gain 1.39% to $60.64.
Cloudera, the leader in enterprise analytic data administration powered by Apache HadoopTM, declared that it has partnered with CSC (CSC), a global leader in next-generation IT services and solutions, with support from Intel, to achieve industry’s most stringent security certifications for CSC’s Big Data Platform as a Service (BDPaaS) offering: PCI and HIPAA. With this achievement, BDPaaS becomes the first Hadoop-based managed service to receive PCI and HIPAA certifications.
The Payment Card Industry Data Security Standard (PCI DSS) is an industry-wide framework for protecting consumer credit card data, and its security compliance standards are generally considered the market’s most stringent. Beyond payment cards, PCI-level security is essential for many industries — counting banking, retail and healthcare — where strict requirements dictate processes for handling sensitive information such as financial data and personally identifiable information.
Computer Sciences Corporation provides information technology (IT) and professional services and solutions primarily in North America, Europe, Asia, and Australia. The company operates through Global Business Services, Global Infrastructure Services, and North American Public Sector segments.
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), inclined 3.68% to $80.25, during its current trading session.
Alnylam Pharmaceuticals, Inc. ( ALNY), a leading RNAi therapeutics company, declared that Chief Judge Patti B. Saris of the United States District Court for the District of Massachusetts granted Alnylam’s summary judgment motion in an inventorship dispute, holding that Professor Brenda Bass, Distinguished Professor at the University of Utah (“Utah”), is not a co-inventor of certain patents, termed the Tuschl II patents, jointly owned by co-defendants the Max Planck Society (“Max Planck”), University of Massachusetts (“UMass”), Massachusetts Institute of Technology (“MIT”), and the Whitehead Institute for Biomedical Research (“Whitehead”), and exclusively licensed to Alnylam.
In 2011 Utah sued Alnylam, Max Planck, UMass, MIT, and Whitehead alleging that Dr. Bass was either the sole or a co-inventor of the Tuschl II patents, seeking correction of inventorship in addition to unspecified monetary damages. In 2015 Utah dropped their sole inventorship claim. The Court found that there was no partnership between Dr. Bass and Dr. Tuschl, which is a pre-requisite for co-inventorship, and also granted the defendants’ motion for summary judgment on Utah’s state law claims. While Utah can appeal this ruling, Alnylam remains firm in its belief that the inventorship of the Tuschl II patents as stated in the issued patents is correct.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. The companys clinical development programs comprise Patisiran and Revusiran, which are in Phase III clinical trials for the treatment of transthyretin-mediated amyloidosis; ALN-AT3 that is in Phase I clinical trial for hemophilia and rare bleeding disorders; ALN-CC5, which is in Phase I/II clinical trial for the treatment of complement-mediated diseases; and ALN-PCSsc that is in Phase I clinical trial for hypercholesterolemia
Big Lots, Inc. (NYSE:BIG), during its Wednesday’s current trading session gained 0.23% to $47.48.
Big Lots (BIG) declared customers will have the opportunity to donate in-store at all 1,464 store locations and online to support Nationwide Children’s Hospital and the lifesaving research and care offered for children from around the country and across the world. The program will run from September 26 through October 31 with 100 percent of the proceeds raised going to support Nationwide Children’s.
Nationwide Children’s is one of America’s largest pediatric healthcare and research centers delivering care for more than 1 million patient visits each year. In the last year alone, the hospital has treated children from 49 states and 41 countries around the world while providing nearly $130 million in charity care and community benefit. Patients travel from around the nation to access lifesaving treatments—many of which are unaccessible anywhere else. Doctors and researchers are revolutionizing children’s healthcare and research at Nationwide Children’s.
Big Lots, Inc., through its auxiliaries, operates as a non-traditional, discount retailer in the United States. The company offers products under various merchandising categories, such as food category that comprises beverage and grocery, candy and snacks, and specialty foods departments; consumables category, which comprises health and beauty, plastics, paper, chemical, and pet departments; soft home category that comprises of fashion bedding, utility bedding, bath, window, decorative textile, and area rugs departments; hard home category, counting small appliances, table top, food preparation, stationery, greeting cards, tools, paint, and home maintenance departments; and furniture and home décor category comprising of upholstery, mattress, ready-to-assemble, case goods, home décor, and frames departments
Finally, Aerie Pharmaceuticals Inc (NASDAQ:AERI), gained 4.01%, to $17.65.
Aerie Pharmaceuticals, Inc. (AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, recently declared that on September 18, dosing commenced of the first patients enrolled in Mercury 1, the Company’s first Phase 3 registration trial of RoclatanTM, a novel once-daily, quadruple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Aerie anticipates total enrollment of about 690 patients in this three-arm one-year safety study with a 90-day efficacy readout. RoclatanTM, which is a fixed-dose combination of Aerie’s product candidate RhopressaTM and latanoprost, the market leading prostaglandin analogue (PGA), demonstrated in its successful Phase 2b clinical trial in 2014 that it has the potential to be the most efficacious therapy for patients with glaucoma and ocular hypertension. The clinical endpoint of Mercury 1 is similar to the efficacy endpoint in the Company’s previous Phase 2b clinical trial and compares RoclatanTM for superiority over each of its two components, with all three arms dosed once daily. The range for the primary endpoint evaluates patients with maximum baseline IOPs ranging from above 20 to below 36 mmHg (millimeters of mercury). The 90-day efficacy results of this study are predictable to be stated in about one year.
Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
